We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Navitoclax (ABT-263) — senolytic use
An investigational Bcl-2/Bcl-xL inhibitor and one of the most-used research senolytics — it clears senescent 'zombie' cells in animal models. Striking preclinical data (rejuvenated aged stem cells, reduced tau pathology), but no human longevity trials and a serious dose-limiting toxicity: it crashes platelets (thrombocytopenia). An investigational drug, not a supplement.
Research compound — not a dietary supplement
Navitoclax is a research compound, not a regulated dietary supplement. It is sold for research or off-label use. The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most Navitoclax studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2014–2026.
Based on 9 studies · 1 meta-analysis · 2 RCTs
Confidence
Moderate confidenceBy outcome
Navitoclax is a potent, well-characterized research senolytic with strong animal evidence (stem-cell rejuvenation, reduced tau pathology), but there are no human longevity trials and its Bcl-xL inhibition causes serious dose-limiting thrombocytopenia — so the longevity use is preclinical-only and high-risk.
10 trials ongoing or recruiting · 24 completed on ClinicalTrials.gov
3 of the completed trials have posted results
Registered trials show research momentum for Navitoclax, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Navitoclax (ABT-263) is an orally bioavailable small molecule that inhibits the anti-apoptotic Bcl-2-family proteins (Bcl-2, Bcl-xL, Bcl-w), tipping vulnerable cells into apoptosis.
In geroscience it is one of the most widely used research senolytics: senescent cells survive partly by overexpressing these pro-survival proteins, so blocking them selectively kills senescent cells.
The preclinical case is strong and influential — navitoclax cleared senescent cells and rejuvenated aged or irradiated hematopoietic and muscle stem cells in mice, and clearing senescent glial cells with it reduced tau-dependent neurodegeneration and cognitive decline in models.
It was originally developed as an anticancer agent and has been tested in oncology trials, so human pharmacology and toxicity are well characterized — which is exactly where the problem lies.
Its mechanism (Bcl-xL inhibition) causes a dramatic, dose-limiting drop in platelets (thrombocytopenia), because circulating platelets depend on Bcl-xL for survival.
This makes chronic senolytic use risky, and much current research focuses on next-generation, platelet-sparing designs (PROTAC degraders, galacto-conjugated 'navitoclax' prodrugs) to keep the senolytic benefit without the bleeding risk.
The honest picture: compelling animal senolytic data, no human longevity or healthspan trials, and a serious toxicity that limits real-world use. Navitoclax is an investigational drug used as a research tool, not a dietary supplement, and self-administration would be dangerous.
The score reflects strong preclinical senolytic evidence offset by zero human longevity data and a severe dose-limiting toxicity.
Navitoclax blocks anti-apoptotic Bcl-2-family proteins that senescent cells (and platelets) depend on for survival, triggering their apoptosis.
By removing the pro-survival shield of senescent cells, it selectively clears them, reducing the senescence-associated secretory phenotype (SASP) and chronic inflammation.
Circulating platelets rely on Bcl-xL for survival, so the same mechanism causes dose-limiting thrombocytopenia — the central safety problem.
How Navitoclax works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid — thrombocytopenia plus anticoagulation is dangerous.
Avoid — cytotoxic investigational agent.
Research-use-only; not safe to self-administer.
Adds to thrombocytopenia/bleeding risk — dangerous combination.
Can raise navitoclax exposure and toxicity.
Tip: Dose-limiting on-target toxicity; requires platelet monitoring in trials.
Tip: Consequence of low platelets; avoid with anticoagulants.
Tip: Monitored in clinical trials.
The current evidence for Navitoclax is insufficient to assign an evidence score, based on 9 indexed studies, including 1 meta-analysis. An investigational Bcl-2/Bcl-xL inhibitor and one of the most-used research senolytics — it clears senescent 'zombie' cells in animal models. Striking preclinical data (rejuvenated aged stem cells, reduced tau pathology), but no human longevity trials and a serious dose-limiting toxicity: it crashes platelets (thrombocytopenia). An investigational drug, not a supplement. Representative study: PMID 25053389.
Dosing for Navitoclax: No validated longevity dose. Senolytic research is preclinical or uses intermittent dosing under strict trial monitoring (largely for the platelet toxicity). Oncology dosing is continuous and causes thrombocytopenia. Not appropriate for self-administration.
Timing is flexible for Navitoclax — consistent daily use matters more than the time of day. Investigational agent; any senolytic dosing is intermittent and trial-monitored for platelet counts.
No consumer dose of Navitoclax is endorsed, so there is no dose at which it can be called safe. Talk to a healthcare provider before taking it. Reported side effects include thrombocytopenia (low platelets), bleeding / bruising, neutropenia / GI effects. How often they occur is not established for all of them. Use caution if any of these apply to you: Bleeding disorders / thrombocytopenia; Concurrent anticoagulants/antiplatelets; Pregnancy (breastfeeding: excluded pending trial protocol and infant-risk evidence).
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Tretinoin (Retin-A)
Too few graded studiesA prescription TOPICAL retinoid (Retin-A, Renova) — the acid form of vitamin A and the gold-standard, best-evidenced topical treatment for photoaging and acne. Multiple double-blind RCTs show it reduces fine wrinkles, mottled hyperpigmentation, and roughness over months, with histologic increases in dermal collagen. Caveats: retinoid dermatitis (irritation, peeling, dryness), photosensitivity, and it is CONTRAINDICATED IN PREGNANCY. Prescription drug, not a supplement; distinct from weaker OTC 'retinol' cosmetics.
Red Yeast Rice
Likely helpsFermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism. Its only head-to-head trial with metformin cited here was a 36-person pilot, which does not show it can replace metformin.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 9 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research